SURPASS-CVOT Results: How Does Tirzepatide Stack Up Against Dulaglutide for Cardiovascular Health? Published: December 17, 2025 | Source: New England Journal of Medicine Tirzepatide, the dual GIP and GLP-1 receptor agonist, has already made waves for its potent effects on … Read More
tirzepatide
SURMOUNT 3 Trial: Tirzepatide in Obesity
Visual Abstract Summary: SURMOUNT-3 Phase 3 Trial Objective: To evaluate the efficacy and safety of tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, in achieving additional weight loss in adults with overweight or obesity who … Read More
SURPASS-6 Trial: Tirzepatide in T2DM
The SURPASS-6 trial, featured in JAMA in October 2023, represents a significant advancement in the treatment of type 2 diabetes. This randomized, phase 3, open-label trial was designed to evaluate the effects of once-weekly subcutaneous (SC) tirzepatide versus thrice-daily prandial … Read More
SURMOUNT-1 Trial: Tirzepatide for Weight Loss in Obesity
2022 SURMOUNT-1 TRIAL M Tirze patide Once Weekly for the Treatment of Obesity Phase 3 double-blind, randomized, controlled trial Objective: To assess the efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and GLP-1 agonist, in treatment of obesity … Read More